Squarepoint
ALDX icon

Squarepoint’s Aldeyra Therapeutics ALDX Stock Holding History

Squarepoint’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
+94,048
New +$162K ﹤0.01% 4066
2024
Q2 		– Sell
-38,193
Closed -$125K – 4004
2024
Q1 		$125K Sell
38,193
-34,771
-48% -$114K ﹤0.01% 3747
2023
Q4 		$256K Buy
+72,964
New +$225K ﹤0.01% 3454
2023
Q2 		– Sell
-67,048
Closed -$666K – 3521
2023
Q1 		$666K Buy
+67,048
New +$474K ﹤0.01% 2141
2022
Q3 		– Sell
-10,964
Closed -$44K – 2946
2022
Q2 		$44K Sell
10,964
-17,328
-61% -$59.6K ﹤0.01% 2718
2022
Q1 		$126K Sell
28,292
-73,187
-72% -$292K ﹤0.01% 2573
2021
Q4 		$406K Buy
101,479
+56,352
+125% +$430K ﹤0.01% 2281
2021
Q3 		$396K Buy
45,127
+26,858
+147% +$246K ﹤0.01% 2090
2021
Q2 		$207K Buy
+18,269
New +$220K ﹤0.01% 2802
2020
Q4 		– Sell
-39,349
Closed -$292K – 2871
2020
Q3 		$292K Sell
39,349
-106,341
-73% -$687K ﹤0.01% 1813
2020
Q2 		$608K Buy
145,690
+115,182
+378% +$421K 0.01% 1196
2020
Q1 		$75K Buy
+30,508
New +$137K ﹤0.01% 1683
2019
Q4 		– Sell
-61,695
Closed -$325K – 2451
2019
Q3 		$325K Sell
61,695
-62,343
-50% -$336K ﹤0.01% 1851
2019
Q2 		$744K Buy
124,038
+48,734
+65% +$367K 0.01% 1439
2019
Q1 		$680K Buy
75,304
+7,099
+10% +$60.3K 0.01% 1322
2018
Q4 		$566K Buy
68,205
+56,505
+483% +$579K 0.01% 1182
2018
Q3 		$161K Buy
+11,700
New +$94.9K ﹤0.01% 1820
2017
Q4 		– Sell
-22,070
Closed -$159K – 2058
2017
Q3 		$159K Buy
+22,070
New +$115K ﹤0.01% 1443

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Squarepoint's ALDX Position: Q2 2026 in Review

Squarepoint opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2026: 94,048 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #4066 among its holdings. This is a return to the name: Squarepoint previously reported a position in ALDX as recently as Q1 2024.

Squarepoint first reported a position in ALDX in Q3 2017 and has held it in 18 quarters since. The position peaked at $744K in Q2 2019. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Squarepoint held 94,048 shares of Aldeyra Therapeutics worth $200K as of Q2 2026.
  • Aldeyra Therapeutics was a new Squarepoint position in Q2 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4066 holding.
  • Squarepoint first reported a position in Aldeyra Therapeutics in Q3 2017 and has held it in 18 quarters since.
  • Squarepoint's Aldeyra Therapeutics position peaked at $744K in Q2 2019.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.